Iziphumo ezikhawulezayo kwimizuzu eyi-15-30 ikiti ye-antigen ekhawulezayo i-AMRDT120

Uvavanyo olukhawulezayo lokufunyanwa komgangatho wokungathathi hlangothi

amajoni omzimba kwi-SARS-CoV-2 okanye izitofu zayo zokugonya kwigazi elipheleleyo, kwiserum, okanye kwiplasma.

Ukucaciswa kwePackage: 40 T/kit, 20 T/kit, 10 T/kit, 1 T/kit.

Uvakalelo olunxulumeneyo: 96.97% (95% CI:83.35% ~99.99%)
Iinkcukacha Ngokuhambelana: 100.00% (95% CI:97.29% ~100.00%)
Ukuchaneka: 99.50% (95% CI:96.94% ~99.99%)

Izingxobo zefoil, ezineekhassste zovavanyo kunye needesiccants *20
Isithinteli sovavanyo *iibhotile ezingama-20;
Iidropha ezilahlwayo*20;
I-Lancet *20
Lodine swab*20
Umyalelo wokusetyenziswa*1

Iziphumo ezikhawulezayo kwimizuzu eyi-15-30 Ikhithi ye-antigen ekhawulezayo ye-AMRDT120 UKUSETYENZISWA OKUHLOSIWEYO
UVavanyo oluKhawulezayo lwe-SARS-CoV-2 lwe-Neutralizing Antibody (COVID-19 Ab) luvavanyo olukhawulezayo lwe-chromatographic immunoassay yokufunyaniswa okusemgangathweni kwee-antibodies ze-SARS-CoV-2 kwigazi lonke, kwiserum, okanye kwiplasma.

Iziphumo ezikhawulezayo kwimizuzu eyi-15-30 Ikhithi ye-antigen ekhawulezayo AMRDT120 PRINCIPLE
UVavanyo oluKhawulezayo lwe-SARS-CoV-2 lwe-Neutralizing Antibody (COVID-19 Ab) lolokubona izilwa-buhlungu ze-SARS-CoV-2 okanye izitofu zayo zokugonya.I-cell surface receptor angiotensin converting enzyme-2 (ACE2) ifakwe kwindawo yovavanyo kunye ne-recombinant receptor-binding domain (RBD) edibeneyo kunye neengqungquthela ezibonisayo.

Ngexesha lovavanyo, ukuba kukho ii-antibodies ze-SARS-CoV-2 ezingathathi hlangothi kwisampulu, iya kusabela ngeprotein ye-RBD-particle conjugate kwaye ingasabeli ngeprotein eqatywe ngaphambili i-ACE2.Umxube ke ufudukela phezulu kwi-membrane yechromatographically ngesenzo se-capillary kwaye ayizukubanjwa yi-antigen eqatywe ngaphambili.UVavanyo oluKhawulezayo lwe-SARS-CoV-2 Neutralizing Antibody Rapid (COVID-19 Ab) luqulathe amasuntswana eproteni e-RBD.Iprotheyini ye-ACE2 ifakwe kwindawo yovavanyo.